Therefore, developing new HD mouse models carrying only 1 copy of mutant Htt with relevant human genetic variations will be critical in precisely determining editing efficiencies and functional consequences of mutant-specific NMD-CRISPR/Cas9 strategies. The gene discussed is HTT; the disease is Huntington disease.